False maltingOf oat -- proprietary patented Ceapro technology-- increases avenanthremides content in oat kernel from 20-80 ppm to 900 --2000 ppm, 30 fold rise in Avenanthremides. So once Ceapro achieves commercial production using false malted oat on continuous basis avenanthremides production will increase several folds and satisfy demands from Aveeno &Neutrogena like products at cheaper production cost imo.